INTRODUCTION
miRNAs are small endogenous non-coding RNAs implicated in the post-transcriptional control of gene expression in developmental, physiological and pathological processes. Biologically active/mature miRNAs bind to partially complementary sequences (miRNA recognition element; MRE) in hundreds of mRNAs, which diminish protein production via mRNA degradation and/or translational repression. miRNA-mediated regulation therefore constitutes a major mechanism to control global gene expression patterns (1) (2) (3) . miRNAs are quickly challenging our understanding of genetic regulation in health and disease, including cancer etiology (4) and the generation and inhibition of anti-tumor immune responses (5) (6) (7) (8) (9) .
Biologically active miRNAs bind to MREs on multiple mRNAs and simultaneously silence multiple target genes. This process can directly or indirectly modulate global gene expression and eventually determines transcriptional programs associated with a specific phenotype.
Since immune responses -including those against tumor antigens -depend on rapid phenotypic changes, it is not surprising that miRNAs have emerged as critical regulators of virtually all immune cell types (5, 7) . miR-155 epitomizes the role of miRNAs in the immune system. miR-155 is basally expressed at low levels in B cells (7, 8) , T cells (10) , macrophages (11) , DCs (7) , and progenitor/stem cell populations (10) . Activation signals such as antigen, Toll-like Receptor (TLR) stimulation and inflammatory cytokines, rapidly increase miR-155 expression in various leukocytic subsets, including bone marrow DCs (BMDCs) and macrophages (7, 8, 11) . Interestingly, BMDCs matured in the absence of miR-155 up-regulate MHC-II and costimulatory molecules, but are incapable of effectively activating T cells (7) .
We previously showed that leukocytes with predominant phenotypic attributes of regulatory DCs (including the expression of CD11c and DEC205) home to perivascular locations in the ovarian cancer microenvironment, where they express multiple immunosuppressive mediators (12) (13) (14) . From their position around blood vessels, these regulatory DCs inhibit the protective function of anti-tumor 4 T-cells infiltrating the tumor from the blood. While specific delivery of RNA oligonucleotides to cancer cells is challenging due to low bioavailability, poor cellular uptake and abundant phagocytic activity of other cell types in the tumor microenvironment (15) , the enhanced endocytic pathways and relative accessibility of ovarian cancer-associated myeloid leukocytes makes them ideal targets for nanocomplex-mediated delivery. Thus, we previously showed that polyethylenimine (PEI)-based nanocomplexes are selectively and avidly taken-up by DCs at ovarian cancer locations, in the absence of any targeting motif (12). Using this optimized system, we now demonstrate that activity of mature miR-155 can be augmented in tumor-associated DCs by delivering novel Dicer-substrate RNA duplexes that mimic the structure of endogenous precursor miR-155 hairpin (Dmi155) and that are 
MATERIALS AND METHODS

Production of PEI-based nanoparticles encapsulating DS RNA duplexes
Endotoxin-free polyethylenimine (PEI) for in vivo experiments "in vivo-jetPEI" was purchased from PolyPlus Transfection. Dicer substrates (Dsi) were synthesized at Integrated DNA Technologies (IDT) using the following chimeric sequences:
Control GFP-specific Dicer substrate (GFP Dsi): In all cases, "r" represents a ribonucleotide and the absence of an "r" indicates a deoxynucleotide. The "plus" strand contains two terminal deoxynucleotides that resemble the loop of endogenous pre-miRNA and that function as cleavage signal for Dicer. The "plus" strand refers to the strand that will give rise to the mature miRNA after Dicer processing and preferential incorporation into the RISC.
To generate PEI-based nanoparticles encapsulating Dsi, 50-100 μg of each annealed duplex were complexed with "in vivo-jetPEI" at an N/P ratio of 6, following the recommendations of the manufacturer (PolyPlus Transfection). For biodistribution experiments, Dsi were fluorescently labeled in the 3' end of the plus strand using Cy3 (IDT). Biotinylated Dsi were also chemically synthesized at IDT and include a Biotin group in the 5' end of the "plus" strand. Thus, after intracellular processing of the Dsi, the mature form of the miRNA remains biotinylated in vivo.
Transfection and in vivo delivery of Dsi
Lipofectamine 2000 (Invitrogen) was used for in vitro transfection of Dsi into HEK293 cells in 96-well plates, following the recommendations of the manufacturer. For in vivo biodistribution, 6 phenotypic and gene silencing experiments, mice bearing ID8-Defb29/Vegf-A tumors (12) for 3-4 weeks were intraperitoneally injected with PEI-Dsi nanoparticles (50 μg of Dsi complexed with "in vivo-jetPEI" at N/P 6, per mouse). In all phenotypic and functional experiments, tumor-associated DCs from mice injected with nanoparticles were sorted from ascites or peritoneal wash samples by flow cytometry on the basis of CD45, CD11c and MHC-II positive expression.
Tumor progression experiments
Wild-type C57BL/6 mice were intraperitoneally injected with 2x10 6 parental ID8 (kindly provided by K. Robby, U. Kansas (16) ) and treatments started 15 days post-tumor injection. 2x10 6 aggressive ID8-Defb29/Vegf-A ovarian carcinoma cells were injected intraperitoneally and treatments started after 8 days. In all cases mice received 50 μg of Dsi complexed with "in vivo-jetPEI" at N/P 6 in glucose 5% at the indicated time points. Some experimental groups were also intraperitoneally injected with 50 μg anti-CD40 antibody (clone FGK4.5) 3 hours prior to administration of PEI-based nanoparticles containing Dsi.
For tumor re-challenge protection experiments, 3x10 6 CD3 + T cells negatively immunopurified from the spleens of tumor-bearing mice treated with PBS (day 32 after tumor challenge) or αCD40 Ab plus Dmi155-PEI nanoparticles (day 61 after tumor challenge; treatments at days 8, 13, 18, 23, 27 and 60) were intravenously transferred into naïve C57BL/6 mice previously irradiated with 300γ (five mice per group). Twenty-four hours later mice were challenged in the flank with ID8-Defb29/Vegf-A ovarian carcinoma cells, as described (14) . Tumor pictures were taken 25 days later. Tumor volumes were calculated by the formula V = 0.5 (L × W 2 ), where L is length and W is width.
7
RESULTS
Dicer-substrate RNA duplexes generate functionally active mature miR-155. miR-155 plays an important role in oncogenesis (9), but is also required for optimal antigen presentation and T cell activation by mature DCs (7). We found that immunosuppressive (13, 14, 20, 21) , showed significantly reduced levels of mature miR-155 ( Figure 1A) . However, in vivo administration of CD40 plus TLR3 agonists, which synergistically transform tumor-associated DCs from immunosuppressive to immunostimulatory (13) , induced a dramatic upregulation of mature miR-155 ( Figure 1B) . We therefore hypothesized that miR-155 upregulation in DCs in vivo at tumor locations could be the crucial event promoting their capacity to elicit therapeutic anti-tumor immunity.
To augment miR-155 activity, we generated novel synthetic Dicer substrate (Dsi) RNA duplexes. To become functionally active, Dsi require processing by Dicer, the same RNAse type III enzyme that processes endogenous miRNA precursors and exogenous siRNAs. In addition, Dsi exhibit markedly enhanced silencing efficiency compared with conventional 21-mer siRNA oligonucleotides (22, 23) . In all cases, we designed a forward (sense) RNA strand containing the sequence of endogenous mature miR-155 followed by two terminal deoxynucleotides in the 3'end. We then generated two structural versions for miR-155 mimetic compounds by using different passenger (antisense) strands: An internally bulged complementary strand that recapitulates the precursor miRNA hairpin (Dmi155); and a perfectly matching, siRNA-like, complementary strand (Dsi155; Figure 1C ).
Control irrelevant bulged or siRNA-like Dsi designed to target GFP were also produced in parallel.
Transfection of HEK293 cells with either Dsi155 or Dmi155 led to a dramatic dose-dependent increase in the intracellular levels of processed miR-155, as detected by mature miRNA-specific stem-8 loop RT-Q-PCR (Figure 1D) . Confirming the selective detection of processed miRNAs by the cellular machinery, negligible signal was detected when synthetic Dsi155 or Dmi155 were directly reversed transcribed and amplified prior to transfection ( Figure 1E) . To determine the functionality of processed miR-155 RNA generated from synthetic RNA, we co-transfected HEK293 cells with a luciferase reporter construct containing the miR-155 MRE of Sfpi1, an experimentally validated target gene of miR-155 (24) . As expected, Dmi155 and, to a significantly lesser extent, Dsi155, rapidly silenced luciferase protein expression, while control (GFP-specific) Dsi had no effect ( Figure 1F) .
Importantly, duplexes did not alter luciferase expression when the reporter constructs lacked the cognate miR-155 MRE ( Figure 1G ). Together, these data demonstrate that synthetic Dsi RNA duplexes can be used to effectively generate functionally active mature miR-155 in the cell, and suggest that a bulged structure may be important for the functionality of the miRNA generated. To confirm the functional activity of miR-155 generated in vivo upon synthetic RNA processing, we analyzed the expression of three different experimentally validated targets of miR-155.
Strikingly, the expression of C/ebpβ (10, 26, 27) and Socs1 (28) was rapidly and potently silenced only in tumor-associated DCs engulfing nanoparticles of bulged Dmi155, but not perfectly matching Dsi155 or irrelevant Dsi (Figure 2, E&F) . In addition, although Dsi155 induced a significant decrease in the expression of Sfpi1 (10, 24) , the silencing effect elicited by bulged Dmi155 was significantly greater ( Figure 2G ). Therefore, while both Dsi155 and Dmi155 are biologically processed into mature miR-155, these data suggest that the structural features of the RNA duplex more closely mimicking the endogenous pre-miRNA hairpin are important for optimal silencing of target genes.
After Dicer-processing, mature miRNAs are loaded by various Argonaute proteins (Ago1-4) into the RNA-induced silencing complex (RISC), a process that guides this multiprotein system to silence target mRNAs via cleavage, translational repression or deadenylation (29) . However, only Ago2 has slicer activity (30) . Notably, we detected significantly greater amounts of mature miR-155 generated from both Dsi155 and Dmi155 by stem-loop RT-Q-PCR in Ago2 immunoprecipitates of peritoneal microenvironmental cells, compared with precipitation using Ago4 or, to an even lesser extent, Ago1 antibodies ( Figure 3B ). Most importantly, significantly higher amounts of mature miR-155 processed from Dmi155 vs. Dsi155 were found in slicer activity-endowed Ago2 pull-downs ( Figure 3B) . Correspondingly, superior recovery of various known miR-155 targets was evidenced in Ago2-immunoprecipitated RNA only upon in vivo delivery of PEI-Dmi155, compared with administration of PEI-Dsi155 (Figure 3C-D) . Together, these results indicate that a bulged structure, similar to that of endogenous pre-miR-155, facilitates the efficient incorporation of mature miR-155 10 into the RISC via optimal loading onto Ago2 and, to a lesser extent, Ago4 and Ago1 proteins. There is no reliable Ago3 antibody for IP experiments and consequently Ago3 association studies could not be realized at this time.
Bulged Dmi155 reverts the tolerogenic activity of ovarian cancer-associated DCs and promotes their capacity to boost anti-tumor immunity.
Since miR-155 is critical for DC-mediated antigen presentation (7) and its expression increases in response to CD40/TLR agonists, we hypothesized that delivery of miR-155 to CD40/TLR- Figure 4E) . Likewise, mice treated with Dmi155 also showed a marked increase in the numbers of splenic T cells secreting Granzyme B upon re-stimulation with tumor antigens (Figure 4F ). These responses were tumor-specific because they were significantly diminished when antigen-presenting cells were pulsed with irrelevant (3T3) cells in independent experiments (Supplemental Figure 1D) . Since tumor-associated DCs harboring increased levels of mature miR-155 exhibited functional properties of highly immunostimulatory antigen-presenting cells, we next determined the immunotherapeutic potential of delivering miR-155 mimetic RNA to ovarian cancer DCs, along with synergistic CD40 agonists (13) . Mice growing orthotopic established ID8 ovarian tumors (16) were treated with agonistic anti-CD40 antibodies plus PEI-complexed control Dsi RNA (GFP-specific), Dsi155 or Dmi155. Importantly, no obvious toxicity or secondary tumor growth in distant organs derived from the uptake of miR-155 mimetic RNA by cancer cells was observed in any case. As we previously reported (12), the intrinsic immunostimulatory activiy of PEI-complexed RNA induced a 12 significant increase of ~50% in the median survival of tumor-bearing mice treated with irrelevant (GFP-specific) Dsi, compared with untreated mice (Figure 5A) . Consistent with the limited immunostimulatory effects on DCs, survival of mice treated with PEI-complexed Dsi155 was not superior to that elicited by the TLR5 agonist PEI alone (12), or by CD40 agonists plus the TLR5 agonist PEI, and was similar to that in mice treated with anti-CD40 antibodies plus irrelevant GFP Dsi ( Figure 5A) . In contrast, treatment with bulged Dmi155 induced significantly superior effects and even abrogated disease progression in 33% of mice, which remained alive 80 days after controls succumbed to the disease ( Figure 5A ). These results demonstrate the therapeutic potential of supplementing miR-155 to tumor-infiltrating DCs in vivo using bulged RNA that mimics the structure of endogenous miR-155, and are consistent with the deficient silencing activity of miR-155 processed from perfectly matching oligonucleotides that merely include the sequence of mature miRNAs.
In addition, when treatments were administered to mice growing more aggressive ID8- To confirm the anti-tumor effects of miR-155 mimetics in the absence of the mRNAs upregulated by CD40 activation, we finally treated aggressive tumor-bearing mice with an identical 13 regimen of only control or miR-155 mimicking compounds. As shown in Figure 5C , corresponding, although obviously weaker effects, were observed. Notably, survival increases resulting from miR-155 supplementation were associated with T cell-dependent protection, because T cells from CD40/Dmi155-treated mice restrained tumor growth upon re-challenge, compared to T cells from untreated mice (Figure 5D) . Together, these results demonstrate that only Dmi155 mimicking the bulged structure of endogenous pre-miR-155 is able to induce therapeutic benefits and synergize with the in situ activation of CD40 to extend survival in hosts bearing established aggressive ovarian carcinomas. Unexpectedly, we also found that Satb1, a master genomic organizer (33), is expressed in tumorassociated DCs and silenced by miR-155. 
In vivo
14
In addition, we found down-regulation of multiple transcripts not previously associated with miR-155. We focused on Cd200, a know mediator of DC-induced tolerance (34). Supporting that Cd200 is indeed a bona fide immunosuppressive target of miR-155, luciferase activity was silenced by Dmi155, but not by irrelevant Dsi, in the presence of the 3'-UTR of Cd200 (Figure 6 ). The specificity of the analysis is supported by the parallel silencing of Satb1, recently confirmed as a target of miR-155, but not of Pdcd4, the expression of which is not significantly altered in vivo (Figure 6 ).
Interestingly, Cd200 is not a predicted target of miR-155 in any major databases. This is not surprising because 56% of published targets of miR-155 are also not contained in any major databases, including Miranda, Targetscan, DianaMT, miRDB, Mirwalk, PITA, RNA22 and PicTar).
Together, these data indicate that the transformation of plastic DCs at tumor locations into immunostimulatory cells by synthetic miR-155 is the result of complex genome-wide transcriptional changes rather than the silencing of a limited set of targets. In addition, our optimization of miRNA mimetics and delivery system provides multiple experimental hints for new targets of individual miRNAs, which should help to improve bioinformatical predictions by providing new clues for the design of more reliable algorithms.
DISCUSSION
Here we show for the first time the feasibility of modulating miRNA activity selectively in ovarian cancer microenvironmental leukocytes using a non-viral approach, which promotes their capacity to elicit protective immunity.
While expression of non-coding RNA in cancer cells can be achieved with viral vectors, the therapeutic use of viruses remains a clinical challenge. In addition, low bioavailability, poor cellular uptake and preferential uptake by abundant phagocytic cells (15) enhanced endocytic pathways and massive infiltration of the myeloid leukocytes that systematically accumulate in solid tumors make them ideal targets for nanocomplex-mediated delivery. Because of its relative accessibility, ovarian cancer-associated leukocytes are an ideal target for this approach.
We selected supplementing miR-155 because silencing of a non-redundant set of targets by this miRNA appears to be required for proper antigen presentation (7). However, miR-155 expression is frequently detected at high levels human cancer, both in solid tumors including breast, colorectal, lung, pancreatic and thyroid carcinomas and in liquid tumors including lymphomas and some acute myeloid leukemias (9, 35) . The association between oncogenesis and effective immunity is not Most importantly for the clinical testing miRNA mimetics, we found that perfectly matching (siRNA-like) and bulged (miRNA-like) duplexes were both processed by tumor-associated DCs to generate mature miR-155. However, miR-155 generated from multiple batches of siRNA duplexes exhibited deficient silencing activity towards target genes in vivo, compared to Dmi155.
Correspondingly, significantly higher amounts of mature miR-155 processed from Dmi155 vs. Dsi155 were found in pull-downs of Ago2, the only Ago variant with slicer activity. miRNAs first associate with Agos as RNA duplexes that require activation, defined as conversion of the RNA duplex into a single stranded miRNA. This activation process is the rate-limiting step in Ago loading, and crucially depends on the thermodynamic instability of RNA duplexes (36). However, the cleavage activation pathway specific to Ago2 appears to be the only one insensitive to RNA thermostability in embryonic fibroblasts (36). It is possible that immune cells behave differently, so that Dmi155 and Dsi155 bind to Ago2 variants with similar affinity, but bulged duplexes with weaker thermodynamic stability are more efficiently processed and activated. Not mutually exclusive, it is also possible that chaperone proteins regulating the upload of small hairpin RNAs onto the RISC complex recognize the difference between a bulged vs. a matching structure in DCs, so that different compositions are incorporated with distinct efficiency. Figure 6 on May 1, 201 cancerres.aacrjournals.org Downloaded from
